Home/Pipeline/Graphene BCI for Parkinson's

Graphene BCI for Parkinson's

Parkinson's Disease

Early ClinicalActive

Key Facts

Indication

Parkinson's Disease

Phase

Early Clinical

Status

Active

Company

Inbrain Neuroelectronics

About Inbrain Neuroelectronics

Inbrain Neuroelectronics is a pioneering private neurotech company developing a novel, graphene-based neural interface platform. Its core technology consists of flexible, high-density (up to 1024 contacts) brain-computer interfaces paired with an implantable neural processor and an AI-powered analytics platform, designed for closed-loop, personalized therapy. The company has achieved significant milestones, including FDA Breakthrough Device Designation for Parkinson's and the first human implant of its graphene BCI, positioning it at the forefront of advanced bioelectronic medicine. Backed by strategic collaborations with entities like Merck KGaA, Inbrain aims to address the vast unmet need in neurological disorders with less invasive, more precise therapies.

View full company profile

Therapeutic Areas

Parkinson's Disease Epilepsy Neurological Disorders

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active